Phase II Amount
$1,099,026
Antibiotic resistant infections are a principal concern for the Department of Defense and society at large due to the current lack of available treatments. Monoclonal antibodies represent a promising drug class that could be applied to antibiotic resistant infections to harness a patients own immune system to effectively combat the invading threat. In this program we continue program development to determine binding epitopes of novel antibody candidates, express candidates, and show infectivity reduction potential in in vitro and in vivo assays.